- Wockhardt shares rose up to 5% Tuesday after a strong rally on Monday
- Stock price reached an intraday high of Rs 1,546 versus Monday's Rs 1,472
- USFDA approved Wockhardt’s Zaynich antibiotic, granting it fast-track status
After a stellar rally on Monday, shares of Wockhardt Ltd. have once again risen in trade on Tuesday and is trading with gains of up to 5%.
The stock is currently trading at Rs 1,546, reaching an intraday high of Rs. 1,566. This compares to Monday's closing price of Rs 1,472, as the positive momentum in the stock continues.
-
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
This rally serves as a major relief for a stock that has given largely flattish return on a year-to-date basis.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Why Is Wockhardt Gaining?
The sharp rally in Wockhardt shares come on the back of Monday's development, as the company confirmed USFDA acceptance for Zaynich antibiotic.
The acceptance from USFDA marks a pivotal moment not just for Wockhardt but for Indian pharma, as it highlights the ability of Indian pharma companies to innovate.
In addition to granting approval, the FDA has also granted Zaynich a fast-track status - an expedited review process that is typically reserved for drugs that show promise in treating serious conditions and addressing unmet medical needs.
Zaynich is a combination drug that merges two components. During clinical trails, the drug has shown 97% efficacy against serious carbapenem-resistant infections, considered among the hardest to treat.
In addition, Zaynich has already been used under compassionate use for critically ill patients in India and the US.
This acceptance from the USFDA may open up significant market opportunities for Wockhardt in the United States, one of the biggest pharmaceutical markets in the world, with Wockhardt now positioning itself as an innovator.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
